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Abstract
Background: Squid, as Onyx, is an ethylene-vinyl alcohol copolymer (EVOH)-based liquid embolic agent developed
for neuroradiologic interventions with poor application in abdominal district. Our aim was to evaluate safety,
complications, and efficacy of transcatheter embolization using the two available formulations Squid-18 and 12, in
30 patients affected by different abdominal diseases.
Results: Transcatheter embolization with Squid, combined with other embolic agents, as poly vinyl alcohol (PVA)
particles, coils and amplatzer plugs, or alone (type 2 endoleak), was performed in 30 patients, as follows: 10 portal
vein embolizations (PVEs), 6 arteriovenous malformations (AVMs), 5 visceral artery aneurysms (VAAs), 4 type 2
endoleaks, 3 preoperative embolizations, 1 acute arterial bleeding, 1 female varicocele. Squid was always
administered using dimethyl sulfoxide (DMSO) compatible microcatheters. Technical success, 30-day clinical success
and complications were assessed.
Technical success was 90%. 3 patients (2 AVMs, 1 VAA) required re-intervention successfully performed in all cases.
Major complications, cases of microcatheter entrapment and DMSO-related poor pain control were not recorded.
30-day clinical success was 93.3%: in 2 patients submitted to PVE a sufficient future liver remnant (FLR) hypertrophy
was not achieved.
Conclusion: Squid was successfully used with low complication rate in many abdominal diseases showing a valid
embolic action either combined with other embolic agents or alone in type 2 endoleak. The availability of different
formulations (Squid-18 and Squid-12) variable for viscosity makes Squid preferable to Onyx as EVOH-based liquid
embolic agent, even though comparable studies in different abdominal districts with a larger cohort of patients will
be necessary.
Keywords: Transcatheter embolization, Squid, Portal vein embolization, Visceral aneurysm, Arteriovenous
malformation, Type 2 endoleak
* Correspondence: venturini.massimo@hsr.it
1Department of Radiology, Scientific Institute H S. Raffaele, Via Olgettina 60,
20132 Milan, Italy
Full list of author information is available at the end of the article
CVIR Endovascular
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Venturini et al. CVIR Endovascular             (2019) 2:8 
https://doi.org/10.1186/s42155-019-0051-7
Introduction
Transcatheter embolization (TE) is a well-established
technique in interventional radiology in which an occlu-
sive agent is delivered through a catheter to obstruct flow
within a targeted blood vessel (Sheth et al., 2017). Each
embolic agent is characterized by its respective strengths
and weaknesses and can be used alone or combined with
other occlusive agents to enhance its embolic power. Em-
bolic agents can also divided into solids, as coils for ex-
ample, and liquids (Brassel & Meila, 2015): liquid embolic
materials include adhesive agents, like acrylates, like
n-butyl cyanoacrylate (n-BCA) (Kim et al., 2017),
non-adhesive agents, such as ethylene-vinyl alcohol co-
polymer (EVOH) (Sadeh-Gonike et al., 2018) and cyto-
toxics, like ethanol (Sakuhara et al., 2015). Coils are
largely used in TE: advantages of coils are their marked
radiopacity and ability of replacement or removal if neces-
sary but their major limit is the difficulty to obtain a
complete occlusion. The advantage of an adhesive liquid
embolic agent as n-BCA is a quick induction of a perman-
ent thrombosis after polymerization. Using non adhesive
liquid embolic agents composed of EVOH copolymer dis-
solved in dimethyl sulfoxide (DMSO) and mixed with mi-
cronized tantalum powder, as Onyx, it is possible to
obtain a slower solidification, a more prolonged injection
time and a reduced risk of microcatheter entrapment than
n-BCA. Onyx, first described in 1990s, represents the
well-known liquid embolic agent widely used in cerebral
arteriovenous malformations (AVMs) (Gemmete et al.,
2009; Singfer et al., 2017; Alturki et al., 2018; Nerva et al.,
2018) and also in abdominal-peripheral applications
(Cobb et al., 2014; Né et al., 2018; Izaaryene et al.,
2016; Regine et al., 2015; Chevallier et al., 2016), particu-
larly in the management of endoleak post Endovascular
Aortic Repair (EVAR) (Marcelin et al., 2017; Ierardi et al.,
2018). Squid is a new DMSO- and EVOH-based liquid
embolic agent which has mainly been used in cerebral
field (Akmangit et al., 2017; Gioppo et al., 2017) with poor
application in abdominal district (Szatmáry et al., 2017). It
is commercially available in Squid-12 (Szatmáry et al.,
2017; Erbahceci et al., 2014) and Squid-18 forms.
Squid-12, due to its lower viscosity with more distal pene-
tration capability, may have additional advantage in AVMs
embolization over Onyx, unavailable in this formulation.
The aim of the present study was to report safety, compli-
cations, and efficacy of transcatheter embolization using
Squid-18 and Squid-12, combined with other embolic




A retrospective review of a prospectively maintained data-
base was performed to collect data about TE procedures in
the abdominal district using Squid-Peri (Emboflu, Gland,
Switzerland) from November 2016 to May 2018. Squid® in
both formulations 18 and 12 was approved in Europe (CE
marking for medical devices) for embolization of lesions in
the peripheral vasculature, including arteriovenous malfor-
mations and hypervascular tumors. Squid-18 and
Squid-12, variable for viscosity, were both used as liquid
embolic agent, based on ethylene vinyl alcohol copolymer
(EVOH) after intra-arterial infusion of the solvent dimethyl
sulfoxide (DMSO). Squid was deliberately used combined
with other embolic agents or alone in different abdominal
diseases requiring TE. The indication to use Squid, simi-
larly to Onyx (Medtronic, Dublin, Ireland), rather than
other embolic agents was deemed necessary to achieve a
more rapid and permanent vessel occlusion.
Written informed consent was obtained from all pa-
tients. Institutional review board approval was not re-
quired because of the retrospective nature of the work.
Technical success, peri-procedural complications, 30-day
clinical success (imaging/clinical data at 1month), and
post-procedural complications were assessed according to
international standard guidelines (Angle et al., 2010): tech-
nical success was defined as an immediate angiographic re-
sult of complete occlusion of target vessel(s); secondary
technical success was considered in case of complete oc-
clusion of target vessel(s) after re-intervention; 30-day clin-
ical success was based on clinical improvements of signs
and symptoms and imaging data. About complications,
minor complications were defined as complications with-
out sequelae or requiring nominal therapy or short hospital
stay for observation (generally overnight); major complica-
tions were defined as: (1) complications that require ther-
apy and minor hospitalization (< 48 h); (2) complications
that require major therapy, unplanned increase in level of
care, prolonged hospitalization (> 48 h); (3) complications
that require permanent adverse sequelae; (4) death. Pa-
tients requiring re-intervention with a further embolization
were also assessed. Embolization procedures performed in
election or in emergency were distinguished. Cases of
microcatheter entrapment or poor pain control during
DMSO infusion were recorded.
Patient selection criteria: Clinical and imaging indications
Patient selection criteria were based on clinical and im-
aging data. Imaging was based on a triphasic multidetec-
tor contrast-enhanced Computed Tomography (CT)
scan (Brilliance 64, Philips Healthcare, Cleveland OH,
USA) performed before embolization procedure and 1
month later, as gold standard technique, even though in
particular cases Magnetic Resonance Imaging (MRI) or
Color Doppler Ultrasound (CDU) were also used. Indi-
cations to transcatheter embolization were shared by cli-
nicians, surgeons and interventional radiologists
according to different selection criteria, tailored to the
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specific abdominal diseases and according to standard
guidelines. Pre-operative portal vein embolization
(PVE) was performed in patients affected by extended
malignant liver tumors, candidates to right hepatec-
tomy, to increase the volumetric ratio of future liver
remnant (FLR) to total liver volume, in case of insuf-
ficient volume of the left hepatic lobe (Shinkawa et
al., 2017; van Lienden et al., 2013). Visceral artery an-
eurysms (VAAs) were embolized in case of diameter
larger than 2 cm or showing progressive enlargement
over time (Venturini et al., 2017; Venturini et al.,
2018). Abdominal arterio-venous malformations
(AVMs) were treated in symptomatic patients (Lv et
al., 2017; Yoon et al., 2016). Type 2 endoleak
embolization was performed in patients showing pro-
gressive enlargement of the aneurysmatic sac post
EVAR with a suspected type 2 endoleak at
CT-angiography (Rahimi et al., 2018; Ribé et al.,
2017). Pre-surgical arterial embolization was per-
formed in case of voluminous masses or hypervascu-
lar tumors (Lau et al., 2013). Varicocele embolization
was performed in case of chronic pelvic pain (Laborda et
al., 2013). Transcatheter embolization with Squid of an
acute bleeding was performed in case of a large arterial
breach with significant extravasation of contrast. The final
decision to use Squid, combined with other embolic
agents (or alone), was taken by the interventional radiolo-
gist based on the angiographic evidence and the specific
scenario. Squid-18 was used to obtain a permanent plug
adjacent to the microcatheter tip for example in TE of
VAAs, while Squid-12 was used to obtain a more distal
penetration for example in PVE.
Transcatheter embolization
All procedures of transcatheter embolization were per-
formed in an angiographic room by interventional radi-
ologists with at least 10 year of experience in the field,
using digital subtraction angiography (DSA) (Philips
Allura Xper FD20, Angio system, Netherlands). Proce-
dures technically varied according to different type of
transcatheter embolization. Squid was always adminis-
tered after a super-selective catheterization with a
DMSO-compatible microcatheter.
PVE patients subgroup
Right PVE was performed in patients with extensive ma-
lignant hepatobiliary disease due to hepatocellular car-
cinoma (HCC), cholangiocarcinoma or colorectal liver
metastases, involving the right hepatic lobe, with insuffi-
cient left hepatic lobe and candidates to right hepatec-
tomy (or right trisectionectomy). Contrast-enhanced CT
was performed before the procedure and 4 weeks after
right PVE to assess future liver remnant (FLR) hyper-
trophy. Pre-procedural data, such as future liver remnant
volume (FLR-V), total estimated liver volume (TELV),
embolized liver volume, the ratio FLRV/TELV and the
same post-procedural data, were collected. For 7 patients,
dynamic 99mTc-mebrofenin hepatobiliary scintigraphy
(HBS) was performed, in order to define an accurate
pre-operative risk analysis (Olthof et al., 2017), evaluating
the total liver-function (TL-F) corrected for body surface
area (BSA) and expressed as %/min/m2 (cut off 2.69%/
min/m2). Technical success was defined as complete oc-
clusion of portal branches of hepatic lobes to be resected.
Clinical success was defined as the achievement of volu-
metric criteria necessary for hepatic resection: an increase
of Future FLR-V above the cut off of 25 of total preopera-
tive liver volume was considered sufficient for a safe resec-
tion in patients with normal liver function; whereas in
patient with compromised liver (e.g. cirrhosis, previous
chemotherapy) a % of FRL-V above the cut off of 40% was
deemed necessary (van Lienden et al., 2013).
Statistical analysis
Descriptive analysis were performed on the dataset and
presented in simple frequencies, proportion and percent-
ages using Microsoft Excel 2011 (Microsoft Corporation,
Redmond, WA, USA) from November 2016. P-values,
calculated by T student test, were considered significant
for values < 0.05. The statistical analyses, the
Kaplan-Meier survival curves and the graph were per-
formed using Graph-Pad Prism software (Version 6;
GraphPad, Inc., San Diego, CA).
Results
General findings
Thirty patients (16 females, 14 males, mean age = 59
years, age range = 24–88 years) affected by different
abdominal diseases were submitted to embolization
with Squid-Peri (Squid-18 in 15 cases, Squid-12 in 8
cases, Squid 18 + 12 in 7 cases) as follows: 10 cases of
PVE (Fig. 1), 6 cases of VAAs (Fig. 2), 5 cases of
AVMs (Fig. 3), 4 cases of type Type 2 endoleak
(Fig. 4), 3 cases of pre-operative arterial embolization
(Fig. 5), one case of female varicocele, and one case
of emergency arterial bleeding following bone marrow
biopsy (Fig. 6). Squid alone was used in 4 patients af-
fected by type 2 endoleak, while in the remaining 26
patients it was used in combination with one or more
than one other embolic agents as follows: PVA parti-
cles in 18 cases, coils in 13 cases, Amplatzer plugs in
3 cases. PVE were mainly performed using Squid and
PVA particles, VAAs embolization using Squid and
coils, AVMs with Squid and variable other embolic
agents, while Amplatzer plugs were used in 3 differ-
ent cases (VAA, AVM, preoperative embolization).
Embolization procedures were performed in election
in 25 cases, in emergency in 5 cases (4 AVMs
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Fig. 1 Portal Vein Embolization (PVE) before right hepatectomy in a patient affected by Cholangiocarcinoma. a Preliminary portography before
right PVE. b Right PVE using PVA particles and Squid-12 (light blue arrows). c Contrast enhanced CT pre-PVE showing an insufficient volume of
left hepatic lobe. d Contrast enhanced CT post-PVE showing an increase of left hepatic lobe, with an increase of FLR-V of 71%. e Contrast
enhanced CT post- right hepatectomy shows hypertrophy of the left hepatic lobe (FLR)
Fig. 2 Visceral artery aneurysm (VAA) embolization. a Contrast-enhanced CT in arterial phase shows a splenic artery aneurysm (white arrow). b
Transfemoral diagnostic angiography of the celiac trunk confirms the presence of the splenic artery aneurysm. c After VAA embolization, DSA
shows aneurysm exclusion, splenic artery occlusion with preserved patency of its distal branches through gastric collaterals. d X-rays show
embolic agents used for splenic artery aneurysm embolization: Squid (light blue arrows), coils (white arrows) and Amplatzer plug (black arrows)
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conditioning metrorrhagia in two cases, hematuria in one
case, pulmonary embolism in one case, and 1 iatrogenic
acute arterial bleeding following bone marrow biopsy).
Neither cases of microcatheter entrapment during
Squid administration, nor cases of poor pain control
during DMSO infusion were recorded.
All data regarding patients characteristics, abdominal
disease, embolization type, Squid and other used em-
bolic agents are reported in Table 1.
Primary and secondary outcomes
Technical success was achieved in 27/30 patients, with
an overall technical success rate of 90%. Three patients
(2 AVMs, 1 VAA) required re-intervention. After re-in-
tervention technical success was achieved in all cases
(100% of secondary technical success). 30-day clinical suc-
cess was achieved in 28/30 patients (93.3%). Two patients
submitted to PVE did not perform right hepatectomy due
to inadequate FLR increase to the required cut off.
Peri-procedural complications
Major peri-procedural complications were not re-
corded. Minor peri-procedural complications rate was
13.3%. Two asymptomatic patients 24 h after splenic ar-
tery aneurysm embolization showed a slight elevation
of amylase levels (peak in one patient of 793 U/L and
321 U/L, respectively), without signs of pancreatitis at
imaging: they were managed conservatively and in both
cases, this pancreatic scree spontaneously resolved with
prolonged hospitalization of one night (3 nights instead
of 2 after the procedure). One of those 2 patients with
distal position of the splenic aneurysm had also a distal
ischemia (less than 10% of the spleen), without peri-
splenic fluid and with no clinical consequences. An-
other patient had a local hematoma spontaneously
resolved due to the femoral catheterization.
Squid administration modality
Two types of Squid were used: Squid-18 and Squid-12,
characterized by high and low viscosity, respectively.
Squid was mainly used in combination with other em-
bolic agents (coils, PVA particles, and Amplatzer plugs)
or alone (type II endoleak) to increase the embolizing
power. Immediately prior to use, Squid was continuously
mixed with a “shaker machine” (time = 20 min) to create
a suspension of tantalum fluoroscopically visualizable.
Squid was always administered using DMSO-compatible
microcatheters: before Squid infusion, microcatheter
dead space was filled with DMSO. Two types of micro-
catheteres were used: Renegade Hi-Flo (Boston Scien-
tific, Natick, MA, USA), characterized by straight tip,
length 135/150 cm, 0.027 in. internal lumen and
Fig. 3 Arteriovenous Malformation (AVM) embolization. a Right transfemoral DSA of the left hypogastric artery shows an uterine AVM (white arrows).
b A superselective embolization with microcatheter of the left uterine artery is performed using PVA particles and Squid-18. c Diagnostic DSA of the
right hypogastric artery. d After bilateral uterine AVM embolization, X-rays show both uterine arteries opacified with Squid (light blue arrows)
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Carnelian 2.2 (Tokai, Medical Products, Sarayashiki Tar-
aga Kasugay-city, Japan) characterized by angled or
cobra-shaped tip, length 135/150 cm, 0.021 in. internal
lumen. The Squid was initially injected for 45 s to substi-
tute the DMSO in the dead space of microcatheter and
then into the target vessel, progressively retrieving the
microcatheter to avoid its trapping, using a 1-ml syringe.
The Squid was more slowly injected (60–90 s) to
minimize DMSO toxicity and to ensure its tolerability
also in case of TE of small vessels.
Procedural data
Right PVE was performed through a right intercostal ap-
proach using a combined ultrasonography- and
fluoroscopy-guided technique to access the portal vein
(Venturini et al., 2005). A peripheral right portal vein
was punctured with a Chiba 21G needle under ultrason-
ography guidance and then the main trunk of portal vein
was catheterized with a standard 4-French catheter.
After a preliminary portography, right PVE was per-
formed after selective catheterization of the segments
V-VI-VII-VIII using poly vinyl alcohol (PVA) particles
(Boston Scientific, Natick, MA, USA), Squid (18 and 12)
and coils in particular cases. If indicated, PVE was ex-
tended to IV and I segment.
All arterial procedures of transcatheter embolization
(VAAs, AVMs, type 2 endoleaks, pre-operative
embolization, acute arterial bleeding) were performed
using a transfemoral approach (transaxillary in one
case). After local anaesthesia, when necessary, a diag-
nostic aortography through a pig-tail catheter (4–5
French) was performed. A selective catheterization
with standard 4-French angiographic catheters, such
as Simmons or Cobra (Cordis, Miami, FL, USA), of
the target artery was performed.
Different strategies of transcatheter embolization tai-
lored for the specific disease were used.
For VAAs, initially the efferent vessels, then the
aneurysm sac and finally the afferent vessel were embo-
lized, progressively retracting the catheter or microcath-
eter according to the “isolation technique” (Ikeda et al.,
2010; Venturini et al., 2017). VAAs embolization was
performed using Squid, pushable (MReye, Cook, Bloom-
ington, IN, USA) or detachable coils (Interlock, Boston
Scientific, Natick, MA, USA) of variable diameter and
length, and in particular cases, also Amplatzer Vascular
Plugs (St Jude Medical, St Paul, MN, USA). The target
artery and the nidus of AVMs were embolized using
PVA particles, Squid, and in particular cases also coils.
One Amplatzer plug was used only in one case of a giant
AVM needing a simultaneous transfemoral arterial and
transjugular approach: the plug was placed to occlude
the right gonadic vein to simultaneously reduce the
AVM outflow and to avoid further episodes of
Fig. 4 Type II endoleak embolization. a Contrast-enhanced CT in arterial phase shows the presence of a type II endoleak post EVAR (white
arrows). b Transfemoral diagnostic DSA of the superior mesenteric artery shows hypertrophy of the Riolano arch. c Further diagnostic DSA
performed by a coaxial microcatheter advanced in the Riolano arc confirms the endoleak opacification (white arrows) sustained by the inferior
mesenteric artery stump. d Microcatheter advancement into the aneurysmatic sac and Squid embolization. e Final angiographic control shows
complete endoleak exclusion
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Fig. 5 Iatrogenic acute arterial bleeding embolization. a Diagnostic DSA shows a significant contrast extravasation (white arrows) due to active
arterial bleeding of a branch of the left hypogastric artery. b Progressive embolization with PVA particles and Squid-18. c After embolization, the
bleeding vessel completely filled of Squid (light blue arrows)
Fig. 6 Preoperative embolization. a Contrast-enhanced CT in arterial phase of a hepatic giant hemangioma. b Contrast-enhanced CT in late
phase. c Diagnostic DSA of the hepatic artery. d Final angiographic control after preoperative embolization using PVA particles and Squid (light
blue arrows)
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pulmonary embolisms (metastatic chorioncarcinoma
conditioning giant pelvic AVM, pulmonary metastases
and embolisms). Type 2 endoleaks were embolized using
Squid alone after catheterization of the superior mesen-
teric artery or the hypogastric artery with standard
4-French angiographic catheters (Cobra, Simmons) and
Table 1 Patients characteristics, abdominal disease, embolization type, Squid and other used embolic agents
Patient Gender Age Symptomatic Abdominal disease Embolization type Emergency/
election
Squid type Vials number Other embolic
agents






Emergency 18 1 PVA + Coils +
Amplatzer Plug
2 F 38 Yes
(metrorrhagia)
AVM Uterine arteries Emergency 18 1 PVA
3 M 77 No Type II endoleak Inferior mesenteric
artery
Election 18 3 No
4 M 82 No Type II endoleak Inferior mesenteric
artery
Election 18 + 12 1 No
5 M 34 Yes (pain) AVM Pelvic Election 18 1 Coils + PVA




Election 18 1 Coils + PVA




Election 18 1 PVA
8 F 55 No VAA Splenic artery Election 18 2 Coils
9 F 62 No VAA Renal artery Election 12 1 Coils
10 F 79 No Colorectal liver
metastases
PVE Election 18 2 PVA + Coils
11 M 77 No Cholangio-Ca PVE Election 12 3 PVA
12 M 74 No Cholangio-Ca PVE Election 18 3 PVA
13 M 70 No HCC PVE Election 12 3 PVA
14 M 79 No HCC PVE Election 18 1 PVA + Coils
15 F 56 No Colorectal liver
metastases
PVE Election 12 1 PVA
16 M 61 No VAA Splenic artery Election 18 2 Coils
17 F 64 No VAA Splenic artery Election 18 1 Coils
18 F 50 Yes (bleeding) Arterial rupture Left hypogastric
artery
Emergency 18 1 Coils + PVA
19 M 55 No Cholangio-Ca PVE Election 12 2 PVA
20 M 78 No Colorectal liver
metastases
PVE Election 12 3 PVA
21 M 77 No HCC PVE Election 18 + 12 2 PVA
22 F 56 No VAA Splenic artery Election 18 1 Coils+Amplatzer
Plug




Election 18 1 Amplatzer Plug
24 M 88 No Type II endoleak Inferior mesenteric
artery
Election 12 1 No
25 F 55 No Cholangio-Ca PVE Election 12 1 PVA
26 M 77 No VAA Left gastric artery Election 18 4 Coils
27 F 35 Yes (chronic
pelvic pain)
Varicocele Hypogastric veins Election 18 2 Coils
28 M 78 No Type II endoleak Ileo-lumbar artery Election 18 1 No
29 F 24 Yes
(metrorrhagia)
AVM Uterine arteries Emergency 18 1 PVA
30 F 30 Yes
(macrohematuria)
AVM Renal artery Emergency 18 1 PVA
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subsequent advancement of a coaxial microcatheter
through Riolano arch-inferior mesenteric artery or
ileo-lumbar artery, respectively. Preoperative
embolization of the target artery was performed usually
1 day before surgery in case of giant masses or hypervas-
cular tumors or pulmonary sequestration (Avsenik et al.,
2015) using Squid and PVA (Amplatzer plug) to
minimize the bleeding risk during surgery. Squid was
used as embolic agent with PVA in case of acute arterial
bleeding due to traumatic or iatrogenic large arterial
rupture. Finally Squid was also used with coils using a
transjugular approach to embolize distal branches of
hypogastric veins in case of female varicocele condition-
ing a pelvic congestion syndrome after a preliminary
phlebography performed with 4-French standard angio-
graphic catheters (Headhunter, Cobra).
PVE subgroup findings
Ten patients affected by cholangiocarcinoma (n = 4),
colorectal liver metastases (n = 3) and HCC (N = 3) can-
didates to right hepatectomy were submitted to right
PVE (segments V-VI-VII-VIII): 4 patients performed
right PVE + IV segment, 2 patients right PVE + IV and I
segment. 3 patients were also submitted to external bil-
iary drainage before PVE due to obstructive jaundice.
Technical success of PVE was 100%, while clinical suc-
cess was 80%: after PVE, 2 patients were not submitted
to right hepatectomy for insufficient growth of FLR-V
demonstrated at contrast-enhanced CT performed 1
month after the procedure. .
The future liver remnant-volume (FLR-V) increased
before PVE and after 4 weeks from 433.57 mL (range
245–647.8 mL) to 648.89 mL (range 371–1099.9 mL). (P
value = 0,019) The mean increase of the future liver
remnant-volume (FLR-V) induced by PVE was 53.55%
(range 17.32–89.72%). After PVE, the %FLR/TELV in-
creased from 30.24% to 43.75%, with a median increase
of 48.29% (range 26.48–105.34%, P value = 0.015). The
mean increase of TL-F after PVE at Dynamic
99mTc-mebrofenin hepatobiliary scintigraphy (HBS) was
5,23%/min/m2 (range 2.2–6.92%/min/m2); the mean in-
crease of FLR-F after PVE was 2.69%/min/m2 (range
0.44–4.95%/min/m2).
All volumetric and clinical data are reported in
Table 2.
Discussion
The choice to use a liquid embolic agent mainly com-
bined with other agents (coils) for TE in various abdom-
inal diseases was made to maximize the embolizing
power with a good level of safety, owing to the poor ten-
dency of the polymerized agent to migrate towards off
target sites. Squid is a non-adhesive liquid embolic agent
well known in cerebral field but with poor application in
abdominal district (Erbahceci et al., 2014). It is com-
posed of ethylene vinyl alcohol (EVOH) copolymer dis-
solved in dimethyl sulfoxide (DMSO) and micronized
tantalum powder for radiopacity. Differently from the
other most known EVOH-based liquid embolic agent
Onyx, Squid is available in different combinations, with
Squid-12 characterized by low density and viscosity.
Squid-18, such as in case of Onyx use, is suggested for
initial plug formation, while the new formulation
Squid-12 can improve vascular penetration and spread
more distally. Another advantage of Squid over Onyx is
related to the reduced percentage (30%) of tantalum
which can improve vessels visualization during
embolization and limit metallic artifacts at imaging
follow-up (Gioppo et al., 2017), as also recently demon-
strated (Pop et al., 2018). Squid was always administered
using DMSO-compatible coaxial microcatheters as
straight Renegade Hi-flo (Boston) or curved Carnelian
(Tokai): the peculiar cobra-shaped tip of Carnelian was
useful in selected cases of marked tortuosity of the target
artery, as for example in VAA (splenic) or type 2 endo-
leak embolization. No technical problems, such as
microcatheter entrapment, were recorded. In the present
study on 30 patients affected by different abdominal dis-
eases, both formulations of Squid were used. Squid-12
was largely used in right PVE to embolize also the
medium-peripheral branches of the right portal vein,
usually after PVA particles administration. Embolization
with Squid-18 was preferred in VAAs and AVMs usually
combined with coils and PVA particles, respectively. The
use of Squid, in association with other embolic agents,
does not represent a limitation but rather a valid option,
which increases the embolizing power. For example, in 6
patients submitted to VAA embolization using Squid
and coils the occlusion process of the target artery was
very rapid. According to the isolation technique (Ikeda
et al., 2010), VAA embolization was successfully per-
formed embolizing subsequently the efferent vessel, the
aneurysmatic sac and the afferent vessel: Squid-18 slowly
injected through the microcatheter during its careful re-
traction was able to produce a stable plug into the target
artery strengthening the embolizing action of the coils:
coils provide the support, while Squid can fill the hol-
lows between the coils. In 2 patients affected by splenic
artery aneurysms, a transient amylases increase after the
procedure, conditioning a prolonged hospitalization of
24 h but spontaneously resolved, was recorded. It was
probably caused by an accidental infusion of DSMO, dif-
ferently from Squid not radiopaque and thus undetect-
able on fluoroscopy, in small pancreatic branches arising
from the splenic artery. Pancreatic branches are probably
more sensitive than other arteries to the DMSO toxicity
(Pamuk et al., 2005). DMSO-infusion, which precedes
Squid administration, must be performed very slowly. In
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our series of 5 patients, AVMs embolization strategy was
initially based on PVA particles to determine nidus or
microcirculation hypoxia, followed by Squid-18 to oc-
clude the feeding arteries. In AVMs, it is mandatory be-
fore Squid administration to embolize nidus using PVA
particles or embosphere (Merit Medical, Jordan, Utah,
USA): the lack of peripheral occlusion with proximal
embolization alone can favor collaterals formation from
other vessels predisposing to relapses and
re-interventions (Conger et al., 2016). Furthermore, in
the case of an acute iatrogenic arterial bleeding Squid
was very useful in emergency to quickly and completely
fill the ruptured artery that presented a large breach with
significant extravasation of contrast. Squid alone was
used in 4 cases of type II endoleak embolization: after
the advancement of a coaxial microcatheter in the Rio-
lano arch or in the ileo-lumbar artery and its placement
in the endoleak sac, the progressive filling with Squid of
the aneurysmatic sac was successfully performed and a
permanent occlusion was obtained. In the past, type 2
endoleak embolization was performed using different
embolic agents such as glue, coils, thrombin and Onyx,
combined or alone (Abullarage et al., 2012; Ierardi et al.,
2017; Khaja et al., 2014). The advantage of using an
EVOH-based liquid embolic agent, as Onyx or Squid, is
related to its capacity to fill completely the sac including
inflow and outflow vessels, forming a more stable plug
than that provided by coils (Ierardi et al., 2017). Another
significant advantage of EVOH-based liquid embolic
agents is their complete detachment from the micro-
catheter tip, not always verifiable after glue infusion.
Usually in type 2 endoleak embolization, after the place-
ment of a standard angiographic in the superior mesen-
teric (or hypogastric) artery, microcatheter is advanced
for a long distance before reaching the endoleak sac.
The risk of an accidental spread of embolizing material
from the microcatheter tip after embolization during its
long retraction for many tens of centimeters without the
protection of the angiographic catheter is potentially
higher using glue than Squid (or Onyx): an accidental
embolization of branches of inferior mesenteric or
ileo-lumbar arteries with consequent ischemia is possible
and it was previously described using glue (Bailey et al.,
2011). Considering the clinical outcome of the whole
population, our findings were globally satisfactory in
terms of technical success, clinical success,
re-intervention and recorded complications. In our het-
erogeneous group of patients, the largest subgroup of
patients (n = 10) was that submitted to right PVE, ex-
tended to IV and I segments in selected cases, to reduce
the risk of postoperative liver failure after right hepatec-
tomy (Loffroy et al., 2015). In the past, different embolic
agents were used for PVE, even though cyanoacrylate
glue is usually considered the ideal embolic agent with
the highest expected rate of liver regeneration (Jaberi et
al., 2016). Onyx was previously used in PVE either in
humans (Né et al., 2018) or in experimental models
(Smits et al., 2012). In our series, Squid and PVA parti-
cles (coils in some cases) were used as embolic agents in
PVE obtaining good outcomes in terms of technical suc-
cess (100%), clinical success (80%), and also future liver
remnant volume increase (more than 50%). In only two
patients future liver remnant volume increase was not
sufficient to perform right hepatectomy.
99mTc-mebrofenin hepatobiliary scintigraphy (HBS) as-
sociated to CT volumetry was useful to completely
evaluate the function of the future liver remnant before
surgery: in previous studies (de Graaf et al., 2010), it was
particularly helpful in case of compromised liver (previ-
ous chemotherapy, cirrhosis). Summarizing in PVE, fur-
ther studies with a larger cohort of patients and
randomized trials will be necessary to establish if Squid
and glue could be comparable in terms of liver regener-
ation induction.
Limitations of the present study are represented by the
heterogeneity of abdominal diseases included, the simul-
taneous use of Squid with other embolic agents, the
small sample size and the relatively short follow-up
period.
Conclusion
In this preliminary experience, Squid was successfully
used with a low complication rate in many abdominal
diseases, showing a valid emboliing action either com-
bined with other embolic agents or alone. The availabil-
ity of the formulationSquid-12 allows a better vascular
penetration and the reduced tantalum concentration
limits metallic artifacts at imaging post embolization
compared to Onyx. However further studies with a lar-
ger cohort of patients will define the role of Squid as
embolic agent in each specific abdominal disease.
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